J.W. Cole Advisors’s MIRA Pharmaceuticals MIRA Stock Holding History

J.W. Cole Advisors’s Portfolio MIRA Stock Details MIRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,501	Closed	-$61.9K	–	1553
2025 Q3	$61.9K	Buy	45,501 +4,846	+12%	+$7.03K	﹤0.01%	1513
2025 Q2	$49.2K	Buy	40,655 +655	+2%	+$756	﹤0.01%	1438
2025 Q1	$39.2K	Buy	+40,000	New	+$45.6K	﹤0.01%	1230

Other funds holding MIRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSI

Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FAB

First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

J.W. Cole Advisors's MIRA Position: Q4 2025 in Review

J.W. Cole Advisors sold out of MIRA Pharmaceuticals (MIRA) in Q4 2025, closing a stake of 45,501 shares — an estimated $61.9K sold.

J.W. Cole Advisors first reported a position in MIRA in Q1 2025 and held it in 3 quarters. The position peaked at $61.9K in Q3 2025. 25 funds tracked by Wall St. Rank hold MIRA as of Q4 2025.

J.W. Cole Advisors reported no remaining MIRA Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
J.W. Cole Advisors sold 45,501 MIRA Pharmaceuticals shares in Q4 2025, an estimated $61.9K.
J.W. Cole Advisors first reported a position in MIRA Pharmaceuticals in Q1 2025 and held it in 3 quarters.
J.W. Cole Advisors's MIRA Pharmaceuticals position peaked at $61.9K in Q3 2025.
25 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q4 2025.

Based on J.W. Cole Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.